Kamax
Financials
Estimates*
EUR | 2017 | 2018 | 2019 |
---|---|---|---|
Revenues | <1m | <1m | <1m |
% growth | - | 4 % | 2 % |
EBITDA | <1m | <1m | <1m |
% EBITDA margin | 2 % | 4 % | 2 % |
Profit | <1m | <1m | <1m |
% profit margin | 1 % | 2 % | 1 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Angel | ||
€440k | Early VC | ||
Total Funding | $484k |
Related Content
Recent News about Kamax
EditKamax, founded in 2013 in Limoges, specializes in advanced polarization imaging technology derived from research at CNRS XLIM and the University of Limoges. This innovative technology allows for the translation and quantification of biological modifications through detailed imaging, making it highly valuable for hospitals, clinical laboratories, and research institutions. Kamax's solutions are particularly beneficial in the cosmetic industry, where they aid in the development and characterization of new products. The company operates in the medical imaging and cosmetic research markets, serving clients who require precise, comprehensive, and rapid diagnostic capabilities. Kamax generates revenue through the sale and licensing of its imaging technology and related services.
Keywords: Polarization imaging, biological modifications, diagnostics, research, cosmetic industry, CNRS XLIM, University of Limoges, medical imaging, technology licensing, innovation.